The intramuscular injection nobody intended
Longer needles reach muscle in lean limbs, and intramuscular delivery of a long-acting depot changes absorption in ways nobody wants.
Priya Ramanathan, PharmD
Page 2 of 7 of this archive, newest first.
Archive — page 2
131 piecesThe effect profile, predicted from an expression map
The receptor populations that produce satiety and the ones that produce nausea overlap substantially. That is why the ceiling of this drug class is where it is, and it is…
The mechanism behind the mechanism
The clinical effect profile is almost fully predictable from where the receptor is expressed, which is unusual and useful.
The interventions with trial support, and the much longer list without
Almost nothing in the standard management repertoire has been tested in a randomised trial in this specific population. We say what is extrapolated and from where.
The wavelength decides which impurities exist
Peptide bonds absorb strongly near 214 nm; aromatic side chains absorb near 280 nm. A method reading at 280 is blind to any fragment lacking an aromatic residue.
What the trials counted as intolerance
We set out the questions that distinguish a symptom to manage from a dose to change.
Six lines that would make an identity statement checkable
None of what a checkable identity statement requires is commercially sensitive, and all of it is known to whoever produced the document.
In-use periods, and the ones nobody can give you
A needle blunts on first use. Reuse is uncomfortable, and it is a documented contributor to lipohypertrophy.
Specification and result are two columns, and only one of them is a measurement
The arithmetic of significant figures, applied to a document that routinely reports four of them.
Target dose, effective dose, and the distance between them
The dose-response curve in this class flattens near its top. That has direct consequences for whether the final rung is worth climbing.
Background rates, and why they matter for attribution
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.
Gallstones during rapid weight loss: drug, or weight loss?
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.
The intramuscular injection nobody intended
Skin thickness at the standard injection sites is approximately two millimetres in adults and varies remarkably little with body mass. That single finding is why short…
Diminishing returns, quantified
Where the curve flattens, what flattens with it, and what does not.
The lowest effective dose is a real concept with almost no data behind it
What the labels permit, what clinicians do, and the size of the gap between them.
What the orforglipron schedule assumes about a person it has never met
The four-week step exists because four to five weeks is approximately how long a once-weekly drug takes to stop rising at a fixed dose. That is a good reason, and it is not…
Why your endoscopist wants to know about your injection
This is the single interaction with ordinary medical care that patients most need to disclose, and it is the one most often not asked about.
What the trials counted as intolerance
Trial discontinuation figures are a floor, not an estimate: trial populations are supported in ways ordinary patients are not.
Rapid weight loss moves eight analytes for reasons that have nothing to do with the drug
Three different explanations for the same abnormal number, and how to tell them apart.
Rapid weight loss moves eight analytes for reasons that have nothing to do with the drug
A substantial proportion of the abnormal results generated during rapid weight loss are consequences of the weight loss rather than findings about the person.